Cargando…
Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma
BACKGROUND: Multiple myeloma (MM) is an incurable disease. The acquisition of resistance to drugs, including immunomodulatory drugs (IMiDs), has a negative effect on its prognosis. Cereblon (CRBN) is a key mediator of the bioactivities of IMiDs such as lenalidomide. Moreover, genetic alteration of C...
Autores principales: | Hirano, Mitsuhito, Imai, Yoichi, Kaito, Yuta, Murayama, Takahiko, Sato, Kota, Ishida, Tadao, Yamamoto, Junichi, Ito, Takumi, Futami, Muneyoshi, Ri, Masaki, Yasui, Hiroshi, Denda, Tamami, Tanaka, Yukihisa, Ota, Yasunori, Nojima, Masanori, Kamikubo, Yasuhiko, Gotoh, Noriko, Iida, Shinsuke, Handa, Hiroshi, Tojo, Arinobu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7989023/ https://www.ncbi.nlm.nih.gov/pubmed/33757580 http://dx.doi.org/10.1186/s13046-021-01909-7 |
Ejemplares similares
-
HDAC Inhibitors Exert Anti-Myeloma Effects through Multiple Modes of Action
por: Imai, Yoichi, et al.
Publicado: (2019) -
CD155 and CD112 as possible therapeutic targets of FLT3 inhibitors for acute myeloid leukemia
por: Kaito, Yuta, et al.
Publicado: (2022) -
Efficacy and Safety of Doubly-Regulated Vaccinia Virus in a Mouse Xenograft Model of Multiple Myeloma
por: Futami, Muneyoshi, et al.
Publicado: (2017) -
The novel multi-cytokine inhibitor TO-207 specifically inhibits pro-inflammatory cytokine secretion in monocytes without affecting the killing ability of CAR T cells
por: Futami, Muneyoshi, et al.
Publicado: (2020) -
CRISPR/Cas9 and AAV mediated insertion of β2 microglobulin-HLA-G fusion gene protects mesenchymal stromal cells from allogeneic rejection and potentiates the use for off-the-shelf cell therapy
por: Meshitsuka, Sohsuke, et al.
Publicado: (2022)